Having trouble accessing articles? Reset your cache.

Sarepta wins approval for second exon-skipping DMD therapy after disputing FDA decision

FDA reversed an August decision that rebuffed Sarepta’s Vyondys 53 golodirsen, granting accelerated approval to the therapy to treat Duchenne muscular dystrophy in patients amenable to exon 53 skipping.

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE